The C-HPP Team for Chromosome 17 has documented meeting the neXt-MP50 Missing Protein Challenge. Protein-level PE1 evidence including MS and protein-protein interaction data from the global proteomics community has reduced the number of PE2,3,4 proteins coded on Chromosome 17 by 50 since the 2016 baseline in neXtProt. As a follow-up to our analysis and prioritization of Chr 17 missing proteins last year, we describe what predictions and guidance were successful in this update and we explain the dynamics of a net reduction of PE2,3,4
RESULTS FOR CHR 17 DURING 2018
Here we report the complex path to a net of 7 fewer PE2,3,4 MPs for Chr 17 during 2018 for neXtProt 2019-01. Figure 1 shows the dynamics underlying this net reduction of 7 Chr 17 MPs during 2018-2019 to reach the total of 50 fewer Chr 17 MPs since 2016. Table 1A shows the 11 PE2, the 1 PE3 (KRTAP9-7), and the 1 PE4 (RNF222) MPs promoted to PE1 in 2018. For all decisions based on MS, full documentation of the uniquely mapping, non-nested peptides of 9 or more amino acids in length is present in PeptideAtlas 2019-01. We list the number of such peptides and the specimen(s) analyzed. In some cases, one or more peptides are from different specimens (see PeptideAtlas).
Among these 13 MPs newly promoted to PE1, 11 are based on MS, 1 on PPI, and 1 on immunohistochemistry (IHC). EVPLL, SLC16A5, TMEM92, and RNF222 are proteins we highlighted with potential stranded peptide spectra 1 (Table 1) , i.e., they already had a singleton qualifying peptide in PeptideAtlas and neXtProt and a second we found in ProteomeXchange;
they are now classified as PE1 based on additional spectral evidence in PeptideAtlas. Among the 11 promoted from PE2 to PE1, we also had identified C17orf64 and RNF112 as priority candidates because there was already one proteotypic peptide in PeptideAtlas; they both, plus ADORA2B, had high transcript TPM values 1 . TMEM92 and KRTAP9-7 were prioritized based on PPI, but then identified by MS, suggesting that, though we prioritized KRTAPs and membrane proteins for PPI based on difficulty in solubilizing membrane proteins and high sequence similarities for KRTAPs, it is still fruitful to look for them in MS data.
Some trends stand out in the MS data for these 13 promoted MPs. CCDC182 and C17orf64 both had proteotypic peptides found in the testis. These MS experiments used a multiple protease strategy; many of the peptides found came from LysC and GluC digestion in addition to trypsin 3 . EVPLL and RNF222 each had a peptide found in the same experiment on saliva, which employed a combination of LysC and trypsin 4 . The use of multiple proteases serves to produce more proteotypic peptides that can be detected by MS, which is especially important for proteins that have relatively few sites for trypsin digestion. Another salient point is the use of nontraditional samples for detecting remaining missing proteins, such as saliva, esophagus (the second EVPLL peptide), colon (SLC16A5), and cancers (melanoma for two peptides for ARL17B). Interestingly, 5 different experiments with Hela cells are represented in Table 1A, suggesting HeLa cells as an area of potential for finding more MPs, a trend which was not noted when previously analyzing the 2018 release of neXtProt for Chromosome 17. However, a largescale reanalysis of 41 publicly-available HeLa cell proteomics datasets found only one missing protein (NX_O75474, chr 10); altogether there are 116 HeLa datasets in PRIDE 5 .
Meanwhile, Table 1B In Table 1C are 4 PE1 proteins demoted by neXtProt to PE2 plus 1 (KRTAP17-1) demoted to PE3. These apparently reflect re-curation in UniProt/Swissprot adopted by neXtProt. In PeptideAtlas, each has either zero (FADS6 and KRTAP1-1) or 1 (GNGT2, TM4SF5, KRTAAP17-1) unique peptide. FADS6 is not found in PA, while KRTAP1-1 has 22 observed peptides, but not 2 uniquely-mapping peptides, so the entry is labeled "representative". Those with 1 peptide are classified as weak or marginally distinguished. Apparently, these were all previously PE1 based on non-MS data that were reassessed.
In Table 1D , former PE2 entries NBR2 (next to BRCA 1 gene) and FAM215A (uncharacterized apoptosis-related protein) were removed, apparently, reflecting reassessments of the quality of the non-protein evidence. Neither has a current entry in neXtProt and neither has any observed peptides in PeptideAtlas, despite predicted observable peptides.
Finally, in Table 1E, 
